MSH6 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant MSH6.
|Application ||WB, IF, E|
|Calculated MW||152786 Da|
|Other Names||DNA mismatch repair protein Msh6, hMSH6, G/T mismatch-binding protein, GTBP, GTMBP, MutS-alpha 160 kDa subunit, p160, MSH6, GTBP|
|Target/Specificity||MSH6 (NP_000170, 931 a.a. ~ 1030 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||MSH6 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a protein similar to the MutS protein. In E. coli, the MutS protein helps in the recognition of mismatched nucleotides, prior to their repair. A highly conserved region of approximately 150 aa, called the Walker-A adenine nucleotide binding motif, exists in MutS homologs. The encoded protein of this gene combines with MSH2 to form a mismatch recognition complex that functions as a bidirectional molecular switch that exchanges ADP and ATP as DNA mismatches are bound and dissociated. Mutations in this gene have been identified in individuals with hereditary nonpolyposis colon cancer (HNPCC) and endometrial cancer.
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. van der Post RS, et al. J Med Genet, 2010 Jul. PMID 20591884.Comprehensive screen of genetic variation in DNA repair pathway genes and postmenopausal breast cancer risk. Monsees GM, et al. Breast Cancer Res Treat, 2010 May 23. PMID 20496165.A Large-scale genetic association study of esophageal adenocarcinoma risk. Liu CY, et al. Carcinogenesis, 2010 Jul. PMID 20453000.One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Vasen HF, et al. Gastroenterology, 2010 Jun. PMID 20206180.MutSbeta exceeds MutSalpha in dinucleotide loop repair. Kantelinen J, et al. Br J Cancer, 2010 Mar 16. PMID 20160730.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.